Citadel Advisors’s Immune Design Corp. IMDZ Stock Holding History

Citadel Advisors’s Portfolio IMDZ Stock Details IMDZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-23,912	Closed	-$82K	–	10354
2018 Q3	$82K	Sell	23,912 -12,247	-34%	-$46K	﹤0.01%	8654
2018 Q2	$165K	Buy	+36,159	New	+$144K	﹤0.01%	8023
2016 Q1	–	Sell	-5,546	Closed	-$111K	–	9266
2015 Q4	$111K	Buy	+5,546	New	+$95.6K	﹤0.01%	6573

Other funds holding IMDZ

Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCPEM

Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citadel Advisors's IMDZ Position: Q4 2018 in Review

Citadel Advisors sold out of Immune Design Corp. (IMDZ) in Q4 2018, closing a stake of 23,912 shares — an estimated $82K sold.

Citadel Advisors first reported a position in IMDZ in Q4 2015 and held it in 3 quarters. The position peaked at $165K in Q2 2018. 64 funds tracked by Wall St. Rank hold IMDZ as of Q4 2018.

Citadel Advisors reported no remaining Immune Design Corp. position as of Q4 2018 after selling out during the quarter.
Citadel Advisors sold 23,912 Immune Design Corp. shares in Q4 2018, an estimated $82K.
Citadel Advisors first reported a position in Immune Design Corp. in Q4 2015 and held it in 3 quarters.
Citadel Advisors's Immune Design Corp. position peaked at $165K in Q2 2018.
64 funds tracked by Wall St. Rank held Immune Design Corp. as of Q4 2018.

Based on Citadel Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.